Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Generation Program prevention study of CAD106 or CNP520 in cognitively unimpaired APOE4 homozygotes at risk for Alzheimer's disease
NL-OMON50176Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Feb 2018
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of amilomotide and umibecestat in Alzheimer's disease (AD) (4 arms), sponsored by Novartis. Primary endpoints: Time-to-event and Alzheimer's Prevention Initiative Preclinical Composite Cognitive test score. Started Feb 2018; status: active, not recruiting.
02
Drugs
amilomotideumibecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON50176.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50176.